New Study Expands Understanding of the Role of RNA Editing in Gene Control

New Study Expands Understanding of the Role of RNA Editing in Gene Control

December 22, 2005

(PHILADELPHIA - December 23, 2005 ) – For many years, scientists thought gene activity was relatively straightforward: Genes were transcribed into messenger RNA, which was processed and translated into the proteins of the body. Certainly, there were many factors governing the transcription process, but gene control happened at the level of the DNA.

In the past few years, however, evidence for a more nuanced understanding of the total genetic system has steadily accumulated. Researchers at The Wistar Institute and elsewhere have been teasing out the details of a process called RNA editing, in which messenger RNA sequence is altered after transcription by editing enzymes, so that a single gene can produce a number of related but distinct variant proteins. Most recently, scientists have discovered an extensive family of small molecules called microRNAs, or miRNAs, that appear to target and inactivate particular messenger RNAs. This targeted gene silencing is now seen as one of the body’s primary strategies for regulating its genome.

Now, in a new study published online in Nature Structural & Molecular Biology, a Wistar-led team of scientists details the convergence of these two post-transcriptional genetic systems. The findings show that precursor miRNAs, like messenger RNAs, are themselves subject to specific RNA editing, the result of which is to suppress miRNA expression and its activity. The importance of understanding these joined processes can be seen in the fact that roles have been identified for miRNAs in embryonic development, cell and tissue differentiation, and, increasingly, in cancer formation.

“A couple of years ago, we started to investigate whether miRNA precursors were being edited in processing,” says Kazuko Nishikura, Ph.D., senior author on the study and a professor in the gene expression and regulation program at The Wistar Institute. “We found that about half of all miRNA precursor molecules are subject to editing. Looking more closely at a particular miRNA precursor found in blood cells, we identified a specific site where editing leads to suppression of the mature miRNA.”

Nishikura’s team demonstrated that two RNA editing enzymes known as ADAR1 and ADAR2, long the focus of study in her laboratory, are able to alter a specific occurrence of the nucleotide adenosine, changing it to inosine in the precursor molecule for miRNA-142, expressed in hematopoietic tissues. This editing had the effect of preventing a key miRNA processing enzyme called Drosha from cutting the precursor miRNA molecule at a critical step in that process.

Looking downstream along the miRNA processing pathway, the scientists also discovered that a molecular complex called RISC played a surprising role. Several components of RISC are known to be involved in normal miRNA processing. But the duties of an identified component of RISC called Tudor-SN were not known. In this study, Tudor-SN was found to be responsible for degrading miRNAs that had been edited in the earlier step, snipping into smaller bits the now useless precursor miRNA molecule precisely at the inosine site resulting from the earlier editing.

Taken together, the results of the study suggest that regulation of the genome is considerably more sophisticated than had been previously understood to be the case.

“People used to think that gene regulation was best done at the very beginning of the production line, which is transcription,” says Nishikura. “Therefore, many scientists investigated transcription factors, activating proteins, and so on. But things have changed, and we now know that genes are controlled at many different levels.”

The lead author on the Nature Structural & Molecular Biology study is Weidong Yang. Additional Wistar-based co-authors are Thimmaiah P. Chendrimada and Qingde Wang. Ramin Shiekhattar, Ph.D., a professor in two programs at Wistar, the gene expression and regulation program and molecular and cellular oncogenesis program, collaborated with senior author Nishikura on the investigation. (Shiekhattar’s own research has contributed to a better understanding of the processing steps that lead to mature miRNAs: See http://www.wistar.org/news_info/pressreleases/pr_11.03.05.htm.) The remaining coauthors on the current study are Miyoko Higuchi and Peter H. Seeburg at the Max Planck Institute for Medical Research in Heidelberg , Germany .

Support for the research was provided by the National Institutes of Health, the March of Dimes, and the Commonwealth Universal Research Enhancement Program of the Pennsylvania Department of Health.

The Wistar Institute is an independent nonprofit biomedical research institution dedicated to discovering the causes and cures for major diseases, including cancer, cardiovascular disease, autoimmune disorders, and infectious diseases. Founded in 1892 as the first institution of its kind in the nation, The Wistar Institute today is a National Cancer Institute-designated Cancer Center focused on basic and translational research. Discoveries at Wistar have led to the development of vaccines for such diseases as rabies and rubella, the identification of genes associated with breast, lung, and prostate cancer, and the development of monoclonal antibodies and other significant research technologies and tools.  Additional information about The Wistar Institute is available on the web at www.wistar.org.

###